Astragaloside IV Restores Autophagy and Inhibits Apoptosis for Podocyte Protection in Diabetic Nephropathy by Inhibiting Notch1 Signaling via SIRT6-Mediated Deacetylation.
Astragaloside IV (AS-IV) has demonstrated efficacy in ameliorating proteinuria and attenuating renal tubular damage in preclinical diabetic nephropathy (DN) models. Despite these multi-target benefits, the molecular mechanisms underlying its podocyte-protective effects remain largely uncharacterized, particularly its p...